Ikarian Capital, LLC Protara Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

$573 Million
Q3 2024

A detailed history of Ikarian Capital, LLC transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 155,712 shares of TARA stock, worth $845,516. This represents 0.05% of its overall portfolio holdings.

Number of Shares

155,712

Previous 180,712 13.83%

Holding current value

$845,516

Previous $375,000 24.27%

% of portfolio

0.05%

Previous 0.15%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.7 - $2.4 $42,500 - $60,000	-25,000 Reduced 13.83%	155,712 $284,000
Q2 2024 Aug 14, 2024	SELL	$1.96 - $4.14 $43,098 - $91,034	-21,989 Reduced 10.85%	180,712 $375,000
Q1 2024 May 15, 2024	BUY	$1.86 - $4.83 $26,108 - $67,798	14,037 Added 7.44%	202,701 $812,000
Q3 2022 Nov 14, 2022	SELL	$2.96 - $4.27 $204,799 - $295,437	-69,189 Reduced 26.83%	188,664 $558,000
Q2 2022 Aug 12, 2022	SELL	$2.8 - $5.33 $108,004 - $205,594	-38,573 Reduced 13.01%	257,853 $756,000
Q1 2022 May 13, 2022	BUY	$4.19 - $6.9 $71,942 - $118,473	17,170 Added 6.15%	296,426 $1.52 Million
Q4 2021 Feb 14, 2022	SELL	$6.15 - $7.76 $1.23 Million - $1.56 Million	-200,739 Reduced 41.82%	279,256 $1.89 Million
Q3 2021 Nov 15, 2021	SELL	$6.38 - $9.3 $668,681 - $974,723	-104,809 Reduced 17.92%	479,995 $3.32 Million
Q2 2021 Aug 16, 2021	SELL	$8.68 - $16.99 $561,925 - $1.1 Million	-64,738 Reduced 9.97%	584,804 $5.7 Million
Q4 2020 Feb 12, 2021	SELL	$16.97 - $25.34 $1.24 Million - $1.85 Million	-72,901 Reduced 10.09%	649,542 $15.7 Million
Q3 2020 Nov 16, 2020	BUY	$16.76 - $31.89 $3.26 Million - $6.2 Million	194,479 Added 36.84%	722,443 $12.2 Million
Q2 2020 Aug 14, 2020	BUY	$22.0 - $60.7 $11.6 Million - $32 Million	527,964 New	527,964 $15.5 Million

Others Institutions Holding TARA

# of Institutions

Shares Held

10.7M

Call Options Held

Put Options Held

1.8K

View Full List

About Protara Therapeutics, Inc.

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $61.2M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

More about TARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Account

Ikarian Capital, LLC Protara Therapeutics, Inc. Transaction History